BIOMAT Database Logo BIOMAT Database Logo

Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease. 2023

Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, KY.

Alloreactive T-effector cells (Teffs) are the major culprit of acute graft-versus-host disease (aGVHD) associated with hematopoietic stem cell transplantation. Ex vivo nonspecific depletion of T cells from the donor graft impedes stem cell engraftment and posttransplant immune reconstitution. Teffs upregulate Fas after activation and undergo Fas ligand (FasL)-mediated restimulation-induced cell death (RICD), an important mechanism of immune homeostasis. We targeted RICD as a means to eliminate host-reactive Teffs in vivo for the prevention of aGVHD. A novel form of FasL protein chimeric with streptavidin (SA-FasL) was transiently displayed on the surface of biotinylated lymphocytes, taking advantage of the high-affinity interaction between biotin and streptavidin. SA-FasL-engineered mouse and human T cells underwent apoptosis after activation in response to alloantigens in vitro and in vivo. SA-FasL on splenocytes was effective in preventing aGVHD in >70% of lethally irradiated haploidentical mouse recipients after cotransplantation with bone marrow cells, whereas all controls that underwent transplantation with nonengineered splenocytes developed aGVHD. Prevention of aGVHD was associated with an increased ratio of CD4+CD25+FoxP3+ T regulatory (Tregs) to Teffs and significantly reduced transcripts for proinflammatory cytokines in the lymphoid organs and target tissues. Depletion of Tregs from the donor graft abrogated the protection conferred by SA-FasL. This approach was also effective in a xenogeneic aGVHD setting where SA-FasL-engineered human PBMCs were transplanted into NSG mice. Direct display of SA-FasL protein on donor cells as an effective means of eliminating alloreactive Teffs in the host represents a practical approach with significant translation potential for the prevention of aGVHD.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053222 Fas Ligand Protein A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS. Antigens, CD178,CD178 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 6,CD178 Antigen,CD95 Antigen Ligand,CD95 Ligand,CD95L,Fas Ligand,Fas Ligand (FasL),FasL Protein,TNF Superfamily, Member 6,Antigen, CD178
D019809 Streptavidin A 60-kDa extracellular protein of Streptomyces avidinii with four high-affinity biotin binding sites. Unlike AVIDIN, streptavidin has a near neutral isoelectric point and is free of carbohydrate side chains. Strepavidin

Related Publications

Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease.
October 2013, Experimental hematology,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
February 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
August 2006, Transplantation,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Fas ligand- mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease.
February 1998, The Journal of clinical investigation,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice.
January 2022, International journal of molecular sciences,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation.
May 1986, Blood,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
The ex vivo toll-like receptor 7 tolerance induction in donor lymphocytes prevents murine acute graft-versus-host disease.
January 2018, Cytotherapy,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Fas-mediated cytotoxicity by intestinal intraepithelial lymphocytes during acute graft-versus-host disease in mice.
July 1997, Gastroenterology,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Neuraminidase pretreatment of donor lymphocytes and graft-versus-host disease.
March 1989, Experimental hematology,
Pradeep Shrestha, and Ali Turan, and Lalit Batra, and Ayse Ece Gulen, and Zhengda Sun, and Helen Tan, and Nadir Askenasy, and Haval Shirwan, and Esma S Yolcu
Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease.
October 1998, Bone marrow transplantation,
Copied contents to your clipboard!